S&P 500   4,274.84 (-0.71%)
DOW   33,978.47 (-0.51%)
QQQ   330.27 (-0.60%)
AAPL   175.68 (+1.53%)
MSFT   292.49 (-0.08%)
META   176.49 (-1.66%)
GOOGL   120.55 (-0.94%)
AMZN   142.87 (-1.32%)
TSLA   924.54 (+0.53%)
NVDA   184.90 (-2.06%)
NIO   20.40 (-2.44%)
BABA   90.63 (-2.18%)
AMD   98.83 (-1.37%)
MU   61.88 (-3.10%)
T   18.52 (-0.27%)
CGC   4.11 (+8.73%)
F   16.15 (-1.70%)
GE   79.96 (-1.37%)
DIS   123.73 (-0.98%)
AMC   22.72 (-8.42%)
PYPL   100.23 (-1.81%)
PFE   49.45 (-0.82%)
NFLX   242.78 (-1.18%)
S&P 500   4,274.84 (-0.71%)
DOW   33,978.47 (-0.51%)
QQQ   330.27 (-0.60%)
AAPL   175.68 (+1.53%)
MSFT   292.49 (-0.08%)
META   176.49 (-1.66%)
GOOGL   120.55 (-0.94%)
AMZN   142.87 (-1.32%)
TSLA   924.54 (+0.53%)
NVDA   184.90 (-2.06%)
NIO   20.40 (-2.44%)
BABA   90.63 (-2.18%)
AMD   98.83 (-1.37%)
MU   61.88 (-3.10%)
T   18.52 (-0.27%)
CGC   4.11 (+8.73%)
F   16.15 (-1.70%)
GE   79.96 (-1.37%)
DIS   123.73 (-0.98%)
AMC   22.72 (-8.42%)
PYPL   100.23 (-1.81%)
PFE   49.45 (-0.82%)
NFLX   242.78 (-1.18%)
S&P 500   4,274.84 (-0.71%)
DOW   33,978.47 (-0.51%)
QQQ   330.27 (-0.60%)
AAPL   175.68 (+1.53%)
MSFT   292.49 (-0.08%)
META   176.49 (-1.66%)
GOOGL   120.55 (-0.94%)
AMZN   142.87 (-1.32%)
TSLA   924.54 (+0.53%)
NVDA   184.90 (-2.06%)
NIO   20.40 (-2.44%)
BABA   90.63 (-2.18%)
AMD   98.83 (-1.37%)
MU   61.88 (-3.10%)
T   18.52 (-0.27%)
CGC   4.11 (+8.73%)
F   16.15 (-1.70%)
GE   79.96 (-1.37%)
DIS   123.73 (-0.98%)
AMC   22.72 (-8.42%)
PYPL   100.23 (-1.81%)
PFE   49.45 (-0.82%)
NFLX   242.78 (-1.18%)
S&P 500   4,274.84 (-0.71%)
DOW   33,978.47 (-0.51%)
QQQ   330.27 (-0.60%)
AAPL   175.68 (+1.53%)
MSFT   292.49 (-0.08%)
META   176.49 (-1.66%)
GOOGL   120.55 (-0.94%)
AMZN   142.87 (-1.32%)
TSLA   924.54 (+0.53%)
NVDA   184.90 (-2.06%)
NIO   20.40 (-2.44%)
BABA   90.63 (-2.18%)
AMD   98.83 (-1.37%)
MU   61.88 (-3.10%)
T   18.52 (-0.27%)
CGC   4.11 (+8.73%)
F   16.15 (-1.70%)
GE   79.96 (-1.37%)
DIS   123.73 (-0.98%)
AMC   22.72 (-8.42%)
PYPL   100.23 (-1.81%)
PFE   49.45 (-0.82%)
NFLX   242.78 (-1.18%)
NASDAQ:TNDM

Tandem Diabetes Care - TNDM Stock Forecast, Price & News

$53.30
-1.45 (-2.65%)
(As of 08/17/2022 03:03 PM ET)
Add
Compare
Today's Range
$53.10
$54.57
50-Day Range
$53.22
$68.97
52-Week Range
$52.08
$155.86
Volume
14,308 shs
Average Volume
1.04 million shs
Market Capitalization
$3.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$103.36

Tandem Diabetes Care MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
93.8% Upside
$103.36 Price Target
Short Interest
Healthy
6.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
0.37mentions of Tandem Diabetes Care in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.66 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.23) to $0.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

260th out of 1,122 stocks

Surgical & Medical Instruments Industry

27th out of 112 stocks

TNDM stock logo

About Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Tandem Diabetes Care Stock Down 0.9 %

TNDM opened at $54.75 on Wednesday. The company has a quick ratio of 5.36, a current ratio of 6.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $3.52 billion, a P/E ratio of -248.86 and a beta of 0.80. Tandem Diabetes Care has a 52 week low of $52.08 and a 52 week high of $155.86. The business's fifty day simple moving average is $59.46 and its 200 day simple moving average is $86.47.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TNDM. Lake Street Capital cut their price objective on Tandem Diabetes Care from $200.00 to $150.00 in a research report on Thursday, August 4th. Robert W. Baird cut their price objective on Tandem Diabetes Care to $76.00 in a research report on Tuesday, August 9th. Citigroup cut their price objective on Tandem Diabetes Care from $107.00 to $98.00 in a research report on Thursday, August 4th. TheStreet cut Tandem Diabetes Care from a "c-" rating to a "d+" rating in a research report on Monday, June 13th. Finally, Cowen cut their price objective on Tandem Diabetes Care from $141.00 to $107.00 in a research report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Tandem Diabetes Care has an average rating of "Hold" and an average price target of $103.36.

Insider Activity at Tandem Diabetes Care

In related news, COO David B. Berger sold 10,097 shares of the stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $65.02, for a total transaction of $656,506.94. Following the sale, the chief operating officer now owns 2,457 shares of the company's stock, valued at $159,754.14. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.20% of the company's stock.

Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Stock News Headlines

Tandem Diabetes Care (NASDAQ:TNDM) PT Lowered to $80.00
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Cut to $150.00
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Cut to $90.00
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Company Calendar

Last Earnings
11/03/2021
Today
8/17/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
Fax
N/A
Employees
2,000
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$103.36
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+93.9%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$15.57 million
Pretax Margin
-1.62%

Debt

Sales & Book Value

Annual Sales
$702.80 million
Cash Flow
$0.50 per share
Book Value
$7.00 per share

Miscellaneous

Free Float
62,808,000
Market Cap
$3.42 billion
Optionable
Optionable
Beta
0.80

Social Links















TNDM Stock - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TNDM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TNDM, but not buy additional shares or sell existing shares.
View TNDM analyst ratings
or view top-rated stocks.

What is Tandem Diabetes Care's stock price forecast for 2022?

7 brokerages have issued twelve-month price targets for Tandem Diabetes Care's stock. Their TNDM share price forecasts range from $49.00 to $150.00. On average, they predict the company's share price to reach $103.36 in the next twelve months. This suggests a possible upside of 88.8% from the stock's current price.
View analysts price targets for TNDM
or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2022?

Tandem Diabetes Care's stock was trading at $150.52 at the beginning of 2022. Since then, TNDM shares have decreased by 63.6% and is now trading at $54.75.
View the best growth stocks for 2022 here
.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our TNDM earnings forecast
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its quarterly earnings data on Wednesday, November, 3rd. The medical device company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.01. The medical device company had revenue of $179.63 million for the quarter, compared to analyst estimates of $172.80 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 2.99% and a negative net margin of 1.72%. During the same period in the previous year, the company posted ($0.09) EPS.

When did Tandem Diabetes Care's stock split?

Tandem Diabetes Care's stock reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $835.00 million-$845.00 million, compared to the consensus revenue estimate of $857.12 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (10.07%), State Street Corp (2.68%), Stephens Investment Management Group LLC (1.31%), Macquarie Group Ltd. (1.03%), Price T Rowe Associates Inc. MD (0.99%) and Voya Investment Management LLC (0.81%). Insiders that own company stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends
.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $54.75.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $3.52 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

The company employs 2,000 workers across the globe.

When was Tandem Diabetes Care founded?

Tandem Diabetes Care was founded in 2006.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.

This page (NASDAQ:TNDM) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.